Rankings
▼
Calendar
ALNY Q3 2016 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
ALNY
Alnylam Pharmaceuticals, Inc.
$42B
Q3 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$14M
Gross Profit
$14M
100.0% margin
Operating Income
-$107M
-781.5% margin
Net Income
-$104M
-762.4% margin
EPS (Diluted)
$-1.21
QoQ Revenue Growth
+56.7%
Cash Flow
Operating Cash Flow
-$76M
Free Cash Flow
-$96M
Stock-Based Comp.
$16M
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$298M
Stockholders' Equity
$1.0B
Cash & Equivalents
$168M
← FY 2016
All Quarters
Q4 2016 →
